Wall Street is not exactly impressed with the Pfizer-Mylan deal By: MarketWatch July 29, 2019 at 12:09 PM EDT EpiPen-maker Mylan NV is merging with Pfizer Inc.’s off-patent drugs business, and Wall Street is not fully on board. Read More >> Related Stocks: Array Technologies Inc Endo Int'l Plc Mylan Pfizer Teva Pharmaceutical Industries ADR